{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"JAMA: 2011-02-02, Vol. 305, No. 5, Author in the Room\u2122 Audio Interview","description":"Interview with Gabriela Schmajuk, MD, author of Receipt of Disease-Modifying Antirheumatic Drugs Among Patients With Rheumatoid Arthritis in Medicare Managed Care Plans. Summary Points: 1. One third of Medicare managed care patients diagnosed with rheumatoid arthritis are not receiving disease-modifying antirheumatic drugs. 2. There is variation in disease-modifying antirheumatic drug receipt based on &quot;accidental factors&quot;: sociodemographics, geographic location, and health plan. 3. Because disease-modifying antirheumatic drug use is the main way to affect outcomes in rheumatoid arthritis, these patient groups and the physicians treating them are a reasonable target for quality improvement interventions.","author_name":"Author in the Room\u2122 Interviews","author_url":"http:\/\/jamanetwork.com\/index.aspx","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/1851980\/height\/90\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/d71635\/\" height=\"90\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/item\/1851980"}